DA VINCI SYSTEMS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

The Da Vinci systems market size is expected to reach US$ 5.30 billion by 2030, from US$ 1.76 billion in 2023, at a CAGR of 17.1% during the forecast period. Da Vinci surgical systems are robotic technologies that assist surgeons in performing minimally invasive surgeries. These systems provide surgeons with improved precision, flexibility, and control during complex procedures. The advantages of Da Vinci surgery include smaller incisions, reduced blood loss, quicker recovery times, and fewer complications. The key drivers of this market include the increasing adoption of minimally invasive surgeries, technological advancements in robotic surgery, and a rising prevalence of chronic diseases. For instance, in October 2022, Medtronic plc, a global healthcare technology leader, announced three significant global market-entrance and indication expansion approvals for its Hugo robotic-assisted surgery (RAS) system. The new system approvals and indications set the stage for significant access across Europe, North America, and Asia, extending the benefits of minimally invasive surgery to new global audiences.

The Da Vinci systems market is segmented by product type, by application, by end user, and by region. By product type, the instruments & accessories segment accounted for the largest market share in 2022. This is due to the recurrent purchase of instruments & accessories compared to robotic systems and the demand for advanced instruments.

Da Vinci Systems Market Regional Insights:

• North America is expected to be the largest market for Da Vinci systems market during the forecast period, accounting for over 59% of the market share in 2022. The growth of the market in North America is attributed to favorable reimbursement policies, greater adoption of advanced technologies, and a high number of robot-assisted surgeries performed in the region. In December 2022, Medtronic plc announced the first patient enrolled in the Expand URO U.S. clinical trial for the Hugo robotic-assisted surgery (RAS) system. The robotic-assisted prostatectomy procedure was performed by Dr. Michael R. Abern at Duke University Hospital in Durham, N.C.
• The Europe market is expected to be the second-largest market for Da Vinci systems market, accounting for over 25.4% of the market share in 2022. The growth of the market is attributed to the rising geriatric population, increasing prevalence of chronic diseases, and continuous product development by major players in the region. According to EU statistics on income and living conditions (EU-SILC), more than one-third (35.2%) of people in the European Union reported having a long-standing (chronic) health problem in 2021.
• The Asia Pacific market is expected to be the fastest-growing market for Da Vinci systems market, with a CAGR of over 13.2% during the forecast period. The growth of the market in Asia Pacific is attributed to improving healthcare infrastructure, rising medical tourism, and increasing awareness about minimally invasive surgeries in the region.

Figure 1. Global Da Vinci Systems Market Share (%), by Region, 2023

To learn more about this report, request sample copy

Analyst Viewpoint:

The Da Vinci systems market is expected to experience steady growth over the next five years. This is due to the increasing demand for minimally invasive surgeries among patients, along with rising awareness about their benefits, such as shorter hospital stays and faster recovery times. Technological advancements leading to enhanced articulation and dexterity offered by newer generation Da Vinci systems are helping drive their adoption across hospitals. However, the high costs involved in purchasing and maintaining these systems remain a restraint on their widespread adoption. Additional training requirements for operating room staff and surgeons to use Da Vinci technology proficiently further add to the overall costs. Geographical expansion into emerging markets will require customized product offerings and pricing to gain acceptance. Procedure type compatibility is another challenge, as not every surgery can be performed using these systems.

Da Vinci Systems Market Drivers:

• Increasing adoption of minimally invasive surgeries: The growing adoption of minimally invasive surgeries such as laparoscopy is a major factor driving the Da Vinci systems market growth. Compared to traditional open surgeries, minimally invasive procedures result in shorter hospital stays, lower readmission rates, and reduced pain. Robotic surgery with the Da Vinci system further enhances the benefits of minimally invasive surgery through improved dexterity, precision, and control. The system provides surgeons with 3D-HD visualization, intuitive instrument movement, and superior ergonomics. This has led to its increased adoption for complex minimally invasive procedures across gynecology, urology, general surgery, cardiothoracic, and head and neck specialties. For instance, according to data published by the National Center for Biotechnology Information (NCBI) in September 2022, in 2016, 2017, and 2018, there were a total of 10.6 million, 10.6 million, and 10.7 million surgical procedures performed, respectively. Out of these, about 17% of the procedures in 2016, 17.4% in 2017, and 18% in 2018 were minimally invasive surgeries.
• Technological advancements in surgical robotics: Continuous advancements in surgical robotics technology such as instrument articulation, motion scaling, and tremor elimination allow for more precise and safer procedures. Intuitive Surgical, the pioneer in robotic surgery, continues to launch new and advanced Da Vinci systems with improved capabilities. For instance, the latest Da Vinci X and Xi systems include thinner arms, longer instrument shafts, and imaging enhancement features compared to their predecessors. The company also launched Da Vinci SP, the first robotic-assisted surgical system optimized for single port procedures. Such technological improvements are fueling the adoption of robotic surgery, thereby driving market growth. For instance, in June 2023, Apollo Hospitals, a pioneer in healthcare innovation, launched the Da Vinci Xi Robotic Surgical System, a groundbreaking advancement in surgical procedures that promises enhanced precision and superior patient care. Cutting-edge technology represents a significant achievement that has the potential to transform surgical healthcare, creating new opportunities for both patients and surgeons.
• Improved clinical outcomes: Numerous clinical studies have demonstrated the clinical benefits of Da Vinci surgery over open and laparoscopic approaches. Robotic surgery has been associated with lower rates of complications, shorter hospital stays, less blood loss, and quicker recovery in procedures such as prostatectomy, hysterectomy, mitral valve repair, and lung resection. Growing evidence of favorable surgical outcomes is encouraging patients and surgeons to opt for robot-assisted procedures using the Da Vinci system. This is expected to propel market growth during the forecast period.
• Rising prevalence of chronic diseases and cancers: The increasing prevalence of chronic conditions such as cardiovascular disease, hernia, gynecological disorders, and cancers requiring surgical treatment is driving the demand for minimally invasive surgical procedures using the Da Vinci system. With its wristed instruments and HD 3D visualization, the system allows complex cancer and reconstructive surgeries to be performed with enhanced precision and control. The rising volume of surgical procedures is therefore expected to support market growth going forward. As per the data provided by World Health Organization on September 16, 2023, chronic diseases are responsible for 41 million deaths annually, which is approximately 74% of all global fatalities. Each year, 17 million people succumb to NCDs before reaching the age of 70, with 86% of these premature deaths occurring in low- and middle-income nations. The majority of NCD-related deaths, accounting for 77%, are concentrated in low- and middle-income countries. The leading causes of NCD deaths include cardiovascular diseases, claiming the lives of 17.9 million individuals each year, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including deaths due to kidney disease caused by diabetes).

Da Vinci Systems Market Opportunities:

• Emerging markets represent significant growth opportunities: Emerging markets such as China, India, Brazil, and Mexico have significant growth potential for Da Vinci surgical systems owing to their underpenetrated nature, rapidly improving healthcare infrastructure, and rising medical tourism. As awareness regarding the benefits of minimally invasive surgery increases in these regions, major players can focus on increasing their footprint by engaging in partnerships, training programs, and regulatory approvals. For instance, intuitive surgical is expanding training centers and distribution partnerships in India to expand robotic surgery adoption. Capturing these high-growth markets will open up substantial opportunities.
• Development of low-cost robotic surgery systems: While Da Vinci leads the surgical robotics space, the development of lower-cost robotic surgery systems presents a major opportunity for new market entrants. Startups such as CMR Surgical, Medtronic, and Johnson & Johnson are working on next-gen, flexible, portable robotic surgery systems for under US$500,000 to improve access to robotic surgery. With pressures to reduce healthcare costs globally, affordable surgical robots could witness high demand from hospitals and ASCs, thereby driving market growth.
• Growing applications in new procedures: The capabilities of Da Vinci and next-gen robotic systems are being explored for an expanding range of surgical procedures beyond urology and gynecology such as cardiothoracic, head and neck, colorectal, and reconstructive surgeries. With enhanced surgical precision, visualization, and maneuverability, these systems can enable better outcomes in complex cases. The increased uptake across new surgical applications represents a significant opportunity for market growth.
• Simulator training for surgeons: Robotic surgery requires specialized skillsets, and extensive training is essential for safe and effective procedures. This presents an opportunity for companies to develop advanced simulation technologies and training programs to assist surgeons in developing robotic surgery skills without risk to patients. Companies like Mimic and 3D Systems provide virtual reality simulators for Da Vinci training. The launch of advanced training tools can help drive wider adoption of robotic surgery.

Da Vinci Systems Market Trends:

• Integration with AI and data analytics: Major companies are integrating AI, machine learning, and data analytics capabilities into their robotic surgery platforms to assist in surgical planning, intraoperative decision-making, and training. For instance, intuitive surgical's Da Vinci Xi has integrated connectivity features that allow procedural data collection, training program assessment and performance evaluation. The application of AI and data science in robotic surgery can potentially improve surgical precision and patient outcomes. For instance, an article published on July 6, 2023, on MDPI described that researchers from the Department of Electrical and Computer Engineering, Wayne State University, USA, have introduced a ChatGPT-enabled daVinci surgical robot system that has the potential to enhance the usability of the surgical platform by providing a more user-friendly interface. The system has the capability to understand spoken instructions from the operator and, using the ChatGPT-powered interface, can translate the spoken sentences and context into specific commands to modify the robot's actions or activate particular functions.
• Development of single port surgical robots: Leading companies are increasingly focusing on developing robotic systems optimized for single-port surgeries, which require only one small incision. Intuitive Surgical's Da Vinci SP is the first U.S. FDAapproved single-port robotic surgical system featuring wristed instruments, 3D visualization, and enhanced flexibility. Other companies, like Titan Medical are also launching robotic platforms purpose-built for single-port procedures. The trend toward single-port robots is expected to continue due to the associated benefits of improved cosmetic results, shorter hospital stays, and faster recovery.
• Robotic tele-surgery and portability: Tele-operated surgical robotics is an emerging trend that allows surgeons to remotely operate robotic systems and conduct surgeries across long distances through console connectivity. Companies are also developing lightweight and flexible surgical robots that can be easily moved within the OR which enhances workflow and accessibility. Versius by CMR Surgical is an early example of a portable and modular robotic surgery system. Such innovations in telesurgery and portability will likely gain traction going forward.
• Robotic surgery in the outpatient setting: There is an increase in ambulatory surgery centers (ASCs) adopting robotic platforms like the Da Vinci Xi and Si systems to perform outpatient procedures in a minimally invasive manner with faster discharge. As robotic surgery continues to grow, its transition to the outpatient setting would represent improved access and cost benefits compared to the hospital setting. Major companies are increasingly targeting ASCs to drive product adoption.

Da Vinci Systems Market Restraints:

• High costs associated with robotic surgery: The high capital cost of purchasing and maintaining Da Vinci surgical systems, estimated between US$1.5 million and US$2.5 million, is a major adoption barrier, especially for smaller hospitals and ASCs. The recurring cost of instruments and accessories is also very high. Insufficient volume and reimbursement may hinder the return on investment, making the costs seem unjustifiable. This limitation has resulted in a lower adoption rate by numerous healthcare institutions. As exemplified in a Nature article from April 2022, the Da Vinci surgical robotic system carries a hefty price of US$ 2 million, prompting inquiries and concerns about its affordability and the potential displacement of more cost-effective treatment options.
• Lack of reimbursement in emerging markets: While developed countries like the U.S. and Europe have favorable reimbursement for robotic surgery procedures, emerging markets still lag in coverage policies. The absence of reimbursement for providers hinders adoption in countries such as China, India, Mexico, and Brazil despite the cost benefits. Improving reimbursement frameworks will help drive growth in these markets.
• COVID-19 impact on elective surgeries: The COVID-19 pandemic resulted in the deferment of many elective surgeries, including robot-assisted procedures. Limited hospital access due to surging cases and healthcare resource constraints adversely impacted procedure volume and system sales. While demand is gradually recovering, the pandemic has restrained market growth in the short term.

Recent Developments:

• In October 2022, Sakra World Hospital, a premier healthcare organization in Bengaluru, acquired a Da Vinci robot to deliver better 3D visualization and precision surgery across all clinical specialties to provide comprehensive robotic care to its patients.
• In May 2022, Dubai Hospital launched the Da Vinci Xi Surgical Robot for performing robotic-assisted minimally invasive surgeries.
• In March 2022, Johnson & Johnson, an American multinational, pharmaceutical, and medical technologies corporation announced the launch of its Ottava robotic surgery system. This new system provides surgeons with enhanced precision and flexibility during minimally invasive procedures.
• In December 2021, Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced that the number of robotic-assisted surgical procedures performed worldwide by surgeons using da Vinci surgical systems has surpassed 10 million.
• In October 2021, Atrium Health Wake Forest Baptist Lexington Medical Center acquired Da Vinci Xi Surgical System, allowing the hospital to offer minimally invasive robotic-assisted surgeries. The Da Vinci Xi Robot is the next frontier for minimally invasive surgery combining the latest assisted surgical technologies that allow for easier access to targeted areas.
• In January 2021, Medtronic received U.S. FDA approval for its Hugo RAS system for robot-assisted spine surgeries. This allows for accurate implant placement and minimal invasiveness.
• In June 2020, Titan Medical, a development stage company, engages in the design and development of SPORT single-port robotic surgical system for application in minimally invasive surgery (MIS) launched its Sport Surgical System for single-port robotic surgery. This provides surgeons with flexibility and improves patient outcomes.
• In September 2021, Intuitive acquired Orpheus Medical and its AI-enabled augmentation technology to enhance the capabilities of da Vinci robotic systems.
• In June 2022, Johnson & Johnson partnered with Verb Surgical to accelerate development of its next-generation digital surgery platform utilizing machine learning.
• In April 2021, Medtronic acquired Digital Surgery, expanding its robotic-assisted surgery offerings with AI and analytics capabilities.
• In February 2019, Huntington Hospital announced the recent acquisition of two da Vinci Xi Surgical Systems, the next generation in robotic surgical equipment. The da Vinci Xi System was designed with the goal of further advancing the technology used in minimally invasive surgery.

Figure 2. Global Da Vinci Systems Market Share (%), by Product Type, 2023

To learn more about this report, request sample copy

Top companies in Da Vinci Systems Market:

• Intuitive Surgical, Inc.
• Johnson & Johnson
• Medtronic
• Stryker
• Smith & Nephew
• Karl Storz
• Applied Medical
• Richard Wolf
• Titan Medical
• Avatera Medical

Definition: The Da Vinci systems market refers to the global market for robotic-assisted surgical systems and related instruments, accessories, and services. Da Vinci surgical systems are robotic technologies that allow surgeons to perform complex and minimally invasive procedures with enhanced precision, flexibility, and control compared to traditional open or laparoscopic surgery. The market is driven by factors such as increasing adoption of minimally invasive surgeries, technological advancements in surgical robotics, improved clinical outcomes, and the rising prevalence of chronic conditions that require surgery. The systems, instruments, accessories, and services assist surgeons in a wide range of surgical procedures, including general, colorectal, gynecological, urological, and cardiothoracic & head and neck surgeries. The market is dominated by intuitive surgical, which has a near monopolistic position.

Few Other Promising Reports in Medical Devices Industry

North America And Europe Minimally Invasive Prostate Cancer Surgery Market

Urology Surgical Instruments Market

Gynecological Devices Market

Colorectal Cancer Screening Market